[go: up one dir, main page]

WO2019036043A3 - A method to generate a cocktail of personalized cancer vaccines from tumor-derived genetic alterations for the treatment of cancer - Google Patents

A method to generate a cocktail of personalized cancer vaccines from tumor-derived genetic alterations for the treatment of cancer Download PDF

Info

Publication number
WO2019036043A3
WO2019036043A3 PCT/US2018/000334 US2018000334W WO2019036043A3 WO 2019036043 A3 WO2019036043 A3 WO 2019036043A3 US 2018000334 W US2018000334 W US 2018000334W WO 2019036043 A3 WO2019036043 A3 WO 2019036043A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cocktail
tumor
generate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/000334
Other languages
French (fr)
Other versions
WO2019036043A2 (en
Inventor
Amitabha Chaudhuri
Papia CHAKRABORTY
Ravi Gupta
Priyanka SHAH
Vasumathi KODE
Sreedhar SANTHOSH
Kayla Renee LEE
Xiaoshan SHI, (shirley)
Malini MANOHARAN
Nitin MANDLOI
Rohit Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDGENOME Inc
Original Assignee
MEDGENOME Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDGENOME Inc filed Critical MEDGENOME Inc
Publication of WO2019036043A2 publication Critical patent/WO2019036043A2/en
Publication of WO2019036043A3 publication Critical patent/WO2019036043A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A42—HEADWEAR
    • A42B—HATS; HEAD COVERINGS
    • A42B3/00—Helmets; Helmet covers ; Other protective head coverings
    • A42B3/04—Parts, details or accessories of helmets
    • A42B3/18—Face protection devices
    • A42B3/20—Face guards, e.g. for ice hockey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés de sélection de vaccins anticancéreux à partir de protéines génétiquement modifiées exprimées par des cellules et des tissus cancéreux de mammifère.The present invention provides methods for screening cancer vaccines from genetically engineered proteins expressed by mammalian cancer cells and tissues.

PCT/US2018/000334 2017-08-16 2018-08-16 A method to generate a cocktail of personalized cancer vaccines from tumor-derived genetic alterations for the treatment of cancer Ceased WO2019036043A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762546411P 2017-08-16 2017-08-16
US62/546,411 2017-08-16
US201762596065P 2017-12-07 2017-12-07
US62/596,065 2017-12-07
US201862679734P 2018-06-01 2018-06-01
US62/679,734 2018-06-01

Publications (2)

Publication Number Publication Date
WO2019036043A2 WO2019036043A2 (en) 2019-02-21
WO2019036043A3 true WO2019036043A3 (en) 2019-03-28

Family

ID=65362567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000334 Ceased WO2019036043A2 (en) 2017-08-16 2018-08-16 A method to generate a cocktail of personalized cancer vaccines from tumor-derived genetic alterations for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2019036043A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020022898A2 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
IL321689A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Cancer vaccines for breast cancer
CN109880894A (en) * 2019-03-05 2019-06-14 杭州西合森医学检验实验室有限公司 The construction method of tumour immunity microenvironment prediction model based on RNAseq
EP4062177A1 (en) * 2019-11-18 2022-09-28 Epivax Therapeutics, Inc. Improved compositions and methods for shared neo-epitope vaccines
JP2023515734A (en) * 2020-02-14 2023-04-14 イルミナ インコーポレイテッド Systems and methods for cancer prognosis
CN114333999A (en) * 2020-12-04 2022-04-12 上海朴岱生物科技合伙企业（有限合伙） A method and system for detection and screening of tumor neoantigens using molecular omics and computational architecture
CN118962105B (en) * 2022-03-15 2025-07-22 上海君赛生物科技有限公司 Tumor specific immune cell marker and application thereof
CN115188415B (en) * 2022-07-12 2024-12-20 复旦大学附属肿瘤医院 A method and device for molecular typing of colorectal cancer based on immune characteristics
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098090A1 (en) * 2002-12-09 2009-04-16 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Vitro immunization
US20110293637A1 (en) * 2010-05-14 2011-12-01 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US20150133321A1 (en) * 2013-11-13 2015-05-14 General Electric Company Quantitative in situ characterization of biological samples
US20160090417A1 (en) * 2012-05-15 2016-03-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20160125129A1 (en) * 2013-05-10 2016-05-05 Biontech Ag Predicting immunogenicity of t cell epitopes
US20160177396A1 (en) * 2014-12-22 2016-06-23 Enzo Biochem, Inc. Comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098090A1 (en) * 2002-12-09 2009-04-16 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Vitro immunization
US20110293637A1 (en) * 2010-05-14 2011-12-01 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US20160090417A1 (en) * 2012-05-15 2016-03-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20160125129A1 (en) * 2013-05-10 2016-05-05 Biontech Ag Predicting immunogenicity of t cell epitopes
US20150133321A1 (en) * 2013-11-13 2015-05-14 General Electric Company Quantitative in situ characterization of biological samples
US20160177396A1 (en) * 2014-12-22 2016-06-23 Enzo Biochem, Inc. Comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system

Also Published As

Publication number Publication date
WO2019036043A2 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
WO2019036043A3 (en) A method to generate a cocktail of personalized cancer vaccines from tumor-derived genetic alterations for the treatment of cancer
EA200801074A1 (en) METHODS OF OBTAINING ARTIFICIAL HYBRID SEEDS
EP4442278A3 (en) Humanized antibodies against c-kit
MX2021008143A (en) Methods for harvesting mammalian cell cultures.
EA202091333A1 (en) METHODS FOR ACTIVATION, MODIFICATION AND EXPANSION OF T-CELLS FOR TREATMENT OF CANCER AND RELATED MALIGNANT DISEASES
EA201791633A1 (en) METHOD OF PRECISE MODIFICATION OF A PLANT BY MEANS OF TRANSIENT EXPRESSION OF THE GENE
PH12021553000A1 (en) Multispecific proteins
PH12015502613A1 (en) Biological markers useful in cancer immunotherapy
MX360823B (en) Individualized vaccines for cancer.
MX380738B (en) METHODS FOR MANIPULATING HIGHLY ACTIVE ALLOGENIC T CELLS FOR IMMUNOTHERAPY.
AU2010273974A8 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EA201790010A1 (en) GAMMA-DELTA T-CELLS AND THEIR APPLICATION
PH12022550373A1 (en) Ex vivo gamma delta t cell populations
IL285631A (en) Methods for producing autologous t cells useful for cancer treatment and compositions thereof
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MX2009009636A (en) Methods of treating ophthalmic diseases.
MX2018013081A (en) METHODS FOR PREDICTING THE UTILITY OF PROTEINS OR PROTEIN FRAGMENTS FOR IMMUNOTHERAPY.
EP2569014A4 (en) PROCESSING METHODS
PH12016502406A1 (en) Cell culture process for producing a protein
PL439808A1 (en) Methods and compositions of cell cultures for the production of antibodies
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
EA201492185A1 (en) METHOD OF OBTAINING RECOMBINANT IDURONAT-2-SULFATASE
WO2009135019A3 (en) Methods and compositions for prostate cancer immunotherapy
EA202091349A1 (en) METHODS OF CELL CULTIVATION
EP3761031A4 (en) METHOD FOR ISOLATING CELL NUCLEI HAVING ENHANCED ANTIGENICITY FROM IMMOBILIZED CELLS OR FFPE TISSUE SECTION, ANTIGEN ACTIVATOR AND ASSOCIATED KIT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846315

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18846315

Country of ref document: EP

Kind code of ref document: A2